Work

P3.12.22 A Phase II Study of Sunvozertinib Combined With Anlotinib in Treatment-Naïve NSCLC With EGFR Sensitive Mutations and Co-Mutations (WU-KONG32)

Year: 2025

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2025.09.884

Authors: Y. Zhang, L. Zeng, W. Jiang

Institution: Hunan Cancer Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415520422

FWCI:

Cites:

Cited by:

Related to: